IRIS
CIVES, MAURO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.375
AS - Asia 2.227
EU - Europa 1.893
SA - Sud America 682
Continente sconosciuto - Info sul continente non disponibili 398
AF - Africa 106
OC - Oceania 6
Totale 10.687
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.178
SG - Singapore 857
IT - Italia 715
BR - Brasile 528
CN - Cina 505
HK - Hong Kong 268
SE - Svezia 221
RU - Federazione Russa 202
VN - Vietnam 195
FI - Finlandia 140
FR - Francia 139
GB - Regno Unito 135
DE - Germania 128
CA - Canada 87
IN - India 75
BD - Bangladesh 66
AR - Argentina 57
ID - Indonesia 53
IQ - Iraq 38
JP - Giappone 31
NL - Olanda 31
MX - Messico 30
ZA - Sudafrica 29
TR - Turchia 27
CI - Costa d'Avorio 25
UA - Ucraina 25
AT - Austria 23
CO - Colombia 22
PL - Polonia 22
BE - Belgio 21
PK - Pakistan 19
VE - Venezuela 19
IE - Irlanda 17
EC - Ecuador 16
LT - Lituania 16
ES - Italia 14
SV - El Salvador 14
CR - Costa Rica 13
PH - Filippine 13
MA - Marocco 12
PY - Paraguay 12
SA - Arabia Saudita 12
CL - Cile 11
CW - ???statistics.table.value.countryCode.CW??? 11
IL - Israele 8
NI - Nicaragua 8
TT - Trinidad e Tobago 8
BO - Bolivia 7
GT - Guatemala 7
KE - Kenya 7
UZ - Uzbekistan 7
HN - Honduras 6
JO - Giordania 6
MY - Malesia 6
PR - Porto Rico 6
RS - Serbia 6
TN - Tunisia 6
UY - Uruguay 6
AL - Albania 5
AZ - Azerbaigian 5
EG - Egitto 5
ET - Etiopia 5
HU - Ungheria 5
MK - Macedonia 5
OM - Oman 5
SC - Seychelles 5
TH - Thailandia 5
BB - Barbados 4
JM - Giamaica 4
PE - Perù 4
AE - Emirati Arabi Uniti 3
AU - Australia 3
DO - Repubblica Dominicana 3
EE - Estonia 3
KZ - Kazakistan 3
NP - Nepal 3
RO - Romania 3
AM - Armenia 2
AO - Angola 2
CH - Svizzera 2
DZ - Algeria 2
GR - Grecia 2
HR - Croazia 2
IS - Islanda 2
LB - Libano 2
MD - Moldavia 2
MM - Myanmar 2
MN - Mongolia 2
MT - Malta 2
NZ - Nuova Zelanda 2
XK - ???statistics.table.value.countryCode.XK??? 2
AG - Antigua e Barbuda 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BS - Bahamas 1
BY - Bielorussia 1
CU - Cuba 1
DK - Danimarca 1
DM - Dominica 1
GA - Gabon 1
Totale 10.281
Salva come PNG Salva come JPEG
Città #
Ashburn 696
Fairfield 502
Singapore 460
Woodbridge 389
San Jose 343
Hong Kong 263
Houston 232
Seattle 221
Chandler 210
Cambridge 204
Beijing 202
Milan 197
Nyköping 186
Wilmington 186
Ann Arbor 123
Council Bluffs 123
Helsinki 109
Los Angeles 90
Lauterbourg 78
New York 77
Rome 75
Dallas 72
Lawrence 64
Ho Chi Minh City 63
Santa Clara 63
Jacksonville 61
Roxbury 58
Bari 50
São Paulo 48
Jakarta 41
Nanjing 39
Columbus 38
Buffalo 36
Des Moines 36
Boardman 35
Chicago 35
London 34
Munich 31
Inglewood 28
Brooklyn 26
Hanoi 25
Tokyo 25
Abidjan 24
Dong Ket 23
Falkenstein 23
Paris 23
Phoenix 23
Redwood City 21
Johannesburg 20
Montreal 20
Brussels 19
San Diego 19
Brasília 18
Nuremberg 18
Warsaw 18
Toronto 17
Turin 17
Princeton 16
Belo Horizonte 15
Chennai 15
Moscow 15
Orem 15
Curitiba 14
Dublin 14
Turku 14
Atlanta 13
Figino 13
Frankfurt am Main 13
North Bergen 13
Bologna 12
Buenos Aires 12
Palermo 12
Rio de Janeiro 12
San Francisco 12
San Salvador 12
Baghdad 11
Düsseldorf 11
Naples 11
Willemstad 11
Elk Grove Village 10
Mexico City 10
Miami 10
Shenyang 10
Stockholm 10
Vienna 10
Dearborn 9
Haiphong 9
Nanchang 9
Porto Alegre 9
Calgary 8
Can Tho 8
Changsha 8
Denver 8
Florence 8
Managua 8
Medellín 8
Padua 8
Pune 8
San José 8
The Dalles 8
Totale 6.647
Salva come PNG Salva come JPEG
Nome #
Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors 274
Gastroenteropancreatic Neuroendocrine Tumors 206
Exosomes in melanoma: A role in tumor progression, metastasis and impaired immune system activity 191
Reviewing the Osteotropism in Neuroendocrine Tumors: The Role of Epithelial-Mesenchymal Transition 189
Everolimus restrains the paracrine pro-osteoclast activity of breast cancer cells 189
Bendamustine overcomes resistance to melphalan in myeloma cell lines by inducing cell death through mitotic catastrophe 183
Osteotropism of neuroendocrine tumors: Role of the CXCL12/ CXCR4 pathway in promoting EMT in vitro 183
Erdheim-Chester disease: A systematic review. 179
Extracellular Vesicles and Epigenetic Modifications Are Hallmarks of Melanoma Progression 179
A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management. 177
The Tumor Microenvironment in Neuroendocrine Tumors: Biology and Therapeutic Implications 172
Management of Asymptomatic Sporadic Nonfunctioning Pancreatic Neuroendocrine Neoplasms (ASPEN) ≤2 cm: Study Protocol for a Prospective Observational Study 172
New insights into the molecular pathogenesis of langerhans cell histiocytosis 171
Immune System Evasion as Hallmark of Melanoma Progression: The Role of Dendritic Cells. 170
Development of anti-somatostatin receptors CAR T cells for treatment of neuroendocrine tumors 166
Parallelism of DOG1 expression with recurrence risk in gastrointestinal stromal tumors bearing KIT or PDGFRA mutations 165
Sirtuins and Cancer: Role in the Epithelial-Mesenchymal Transition 165
The Role of Cytotoxic Chemotherapy in Well-Differentiated Gastroenteropancreatic and Lung Neuroendocrine Tumors. 163
NETs: Organ-related epigenetic derangements and potential clinical applications 159
An imbalance between Beclin-1 and p62 expression promotes the proliferation of myeloma cells through autophagy regulation. 158
An update on Merkel cell carcinoma 157
Analysis of the immune landscape of small bowel neuroendocrine tumors 152
Cerebellar ataxia and exercise intolerance in Erdheim-Chester disease 143
Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors 142
The management of refractory carcinoid syndrome: challenges and opportunities ahead 141
Analysis of Postoperative Recurrence in Stage I-III Midgut Neuroendocrine Tumors 141
SNPs in predicting clinical efficacy and toxicity of chemotherapy: Walking through the quicksand 140
Evaluating Risks and Benefits of Evolving Systemic Treatments of Neuroendocrine Tumors 137
DAXX mutations as potential genomic markers of malignant evolution in small nonfunctioning pancreatic neuroendocrine tumors 133
A phase II study of axitinib in advanced neuroendocrine tumors 131
Lenalidomide in multiple myeloma: current experimental and clinical data 130
The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors 128
Adoptive T-cell immunotherapy in digestive tract malignancies: Current challenges and future perspectives 126
Lanreotide dopo octreotide LAR nel pNET in progressione: descrizione di un caso 125
Angiogenesis in NENs, with a focus on gastroenteropancreatic NENs: from biology to current and future therapeutic implications 124
Efficacy and Toxicity Analysis of mFOLFIRINOX in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms 122
Effect of vitaxin on hyperactive osteoclastogenesis in multiple myeloma: a preclinical study 121
Will clinical heterogeneity of neuroendocrine tumors impact their management in the future? Lessons from recent trials 121
1101MO Development of CAR T-cells for future treatment of NETs 121
Role of Bone Targeting Agents in the Prevention of Bone Metastases from Breast Cancer 120
Cell fusion in myeloma marrow microenvironment: role in tumor progression 119
Radionuclide Therapy for Neuroendocrine Tumors 118
Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors 118
Local treatment for focal progression in metastatic neuroendocrine tumors 117
Assessment of bone turnover markers and DXA parameters to predict bone metastasis progression during zoledronate treatment: a single-center experience 115
Bone Metastases in Neuroendocrine Tumors: Molecular Pathogenesis and Implications in Clinical Practice 115
The psychological impact of COVID-19 pandemic on patients with neuroendocrine tumors: Between resilience and vulnerability 114
An update on gastroenteropancreatic neuroendocrine tumors 112
Novel Lenalidomide-based combinations for treatment of multiple myeloma 112
Adamantinoma-like Ewing sarcoma of the salivary glands: a case report and systematic literature review 111
Modified staging classification for pancreatic neuroendocrine tumors on the basis of the American Joint Committee on Cancer and European Neuroendocrine Tumor Society Systems 111
In search of a bone metastasis (BM) gene signature in circulating tumour cells (CTCs) from stage IV breast cancer (BC) patients 111
Non-Melanoma Skin Cancers: Biological and Clinical Features 111
Treatment strategies for metastatic neuroendocrine tumors of the gastrointestinal tract. 110
The current status of somatostatin analogs in the treatment of neuroendocrine tumors and future perspectives 106
A Phase II Study of Ibrutinib in Advanced Neuroendocrine Neoplasms 106
Local treatment for focal progression in metastatic neuroendocrine tumors 103
Circulating tumour cells and their association with bone metastases in patients with neuroendocrine tumours 102
Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors 102
Sensitivity and Specificity of the NETest: A Validation Study 100
Management of NETs in the Precision Medicine Era 97
Therapy for locoregional disease: pancreas 96
Higher frequency of isolated PMS2 loss in colorectal tumors in Colombian population: preliminary results 95
Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Any Benefit When KI-67 is ≥10%? 95
Epidemiology of gastroenteropancreatic neuroendocrine neoplasms: a review and protocol presentation for bridging tumor registry data with the Italian association for neuroendocrine tumors (Itanet) national database 90
Advanced small-bowel well-differentiated neuroendocrine tumours: An international survey of practice on 3rd-line treatment 90
Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): A study protocol 88
Reversal of MYB-dependent suppression of MAFB expression overrides leukaemia phenotype in MLL-rearranged AML 87
EPB41L5 is Associated with the Metastatic Potential of Low-grade Pancreatic Neuroendocrine Tumors 82
Sequencing Treatments in Patients with Advanced Well-Differentiated Pancreatic Neuroendocrine Tumor (pNET): Results from a Large Multicenter Italian Cohort 81
An Immunohistochemical Score as Predictor of the Bone Metastasis Risk in Patients with NETs 81
The future of cellular therapy for the treatment of renal cell carcinoma 80
Extrapulmonary Neuroendocrine Carcinomas: Current Management and Future Perspectives 80
A challenge in emergency department: a case report of oxaliplatin-induced Kounis syndrome 75
Antiproliferative Systemic Therapies for Metastatic Small Bowel Neuroendocrine Tumours 72
Neuroendocrine tumors 69
Novel immunotherapy strategies for treatment of neuroendocrine neoplasms 68
Management of asymptomatic sporadic non-functioning pancreatic neuroendocrine neoplasms no larger than 2 cm: interim analysis of prospective ASPEN trial 61
Impact of the SARS-CoV2 pandemic dissemination on the management of neuroendocrine neoplasia in Italy: a report from the Italian Association for Neuroendocrine Tumors (Itanet) 59
Epidemiology and geographic clustering of Erdheim-Chester disease in Italy and France 57
Mixed neuroendocrine non-neuroendocrine tumors: The quest for evidence 56
Radioligand therapy in the therapeutic strategy for patients with gastro-entero-pancreatic neuroendocrine tumors: a consensus statement from the Italian Association for Neuroendocrine Tumors (Itanet), Italian Association of Nuclear Medicine (AIMN), Italian Society of Endocrinology (SIE), Italian Association of Medical Oncology (AIOM) 56
A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas 55
The impact of COVID-19 on the management of neuroendocrine tumors (NETS): An international NET CONNECT survey of NET patients and healthcare professionals treating net patients 53
Is NETTER-2 a practice-changing trial? 51
SPINK2 silencing suppresses leukemic proliferation and restores myeloid commitment via MECOM downregulation in acute myeloid leukaemia 49
The Role of Radioligand Therapy in Gastroenteropancreatic Neuroendocrine Tumors: An Italian Expert Opinion 44
In Defense of Neuroendocrine Tumor Trials 42
Peptide receptor radionuclide therapy in G3 gastroenteropancreatic neuroendocrine tumors: a missed opportunity for European patients? 40
White paper on best practices for translational research in neuroendocrine neoplasms 40
Pancreatic neuroendocrine neoplasms (pNENs): Genetic and environmental biomarkers for risk of occurrence and prognosis 36
Enhancing patient-centered care with AI: a study of responses to neuroendocrine neoplasms queries 33
COVID-19 in patients with neuroendocrine neoplasms: 2-year results of the INTENSIVE study 27
Diagnosis and treatment of paragangliomas and pheochromocytomas: a survey from the Italian Association for Neuroendocrine Tumors 23
Totale 10.687
Salva come PNG Salva come JPEG
Categoria #
all - tutte 45.135
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 45.135
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022380 0 0 0 10 17 50 14 18 38 37 71 125
2022/2023636 91 111 47 31 37 92 19 87 82 2 17 20
2023/2024313 19 55 14 38 35 63 18 11 6 13 4 37
2024/20251.610 49 27 128 83 57 129 162 129 96 164 207 379
2025/20263.977 557 200 255 472 409 210 380 143 447 379 152 373
2026/20271.145 154 176 240 575 0 0 0 0 0 0 0 0
Totale 10.687